leadf
logo-loader
viewThoughtful Brands Inc.

Mota Ventures taps Dr Markus Backmund as director of clinical research for psychedelic medicine subsidiary Verrian GmbH

The company said it was “thrilled” to be working with Dr Backmund in groundbreaking psychedelic and cannabis research

Mota Ventures - Mota Ventures taps Dr Markus Backmund as director of clinical research for psychedelic medicine subsidiary Verrian GmbH
Dr Backmund serves as chair of the German Society of Addiction Medicine and is regarded as a pioneer in the field of addiction medicine

Mota Ventures Corp (CSE:MOTA) (OTCMKTS:PEMTF) announced on Friday that it has appointed Professor Markus Backmund, as principal investigator and director of clinical research for its wholly-owned psychedelic medicine subsidiary, Verrian GmbH.

Dr Backmund serves as chair of the German Society of Addiction Medicine and is a pioneer in the field of addiction medicine.

Mota revealed on June 2 that it had completed its C$20 million acquisition of European psychedelic medicine company Verrian, which specializes in products related to addiction reduction, with a lazer focus on alcohol and opiates. The company operates a 110,000 square-foot pharmaceutical manufacturing facility in Radebuel, Germany.

READ: Mota Ventures appoints US actor and musician Roger C Clinton as member of Verrian’s advisory board

Mota said Dr Backmund will play a “vital role” in spearheading the research efforts of its addiction medicine experts, resulting “in best of breed psychedelic derived treatments for the global marketplace.”

In a statement, Mota Ventures CEO Ryan Hoggan said: “We’re honoured to be working with a pioneer in addiction medicine, an authentic patient-first specialist like Dr Backmund, who has worked his entire career to change how patients who suffer from addiction are treated.”

He added: “We are thrilled to be working with him in ground-breaking psychedelic and cannabis research as he continues to seek new treatments to help patients overcome addiction”.

Dr Backmund is a medical doctor and specialist in infectious disease, internal medicine, emergency medicine, and addiction. He is also a professor at Ludwig Maximilians University in Munich, and the founder and co-editor of “Suchtmedizin” - the specialist Addiction Medicine Journal - and is the five-time chairman of the Board of the German Society for Addiction Medicine. He also runs the private clinic Praxiszentrum im Tal, an in-patient recovery center in Starnberg, Germany.

“The professional, human and sociopolitical challenges make addiction medicine the exciting field of medicine for me,” said Dr Backmund.

In 1991, Dr Backmund’s groundbreaking research project on “Qualified Withdrawal Treatment” evoked criticism. However, the results of his project are now the gold standard for alternative treatment methods in Germany. His approach to alternative addictions medicine focused on empirical results and on best outcomes for his patients, substantiating that patients need not suffer the mental and physical afflictions associated with withdrawal in order to conquer addiction.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Thoughtful Brands Inc.

Price: 0.08 CAD

CSE:TBI
Market: CSE
Market Cap: $16.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Thoughtful Brands Inc. named herein, including the promotion by the Company of Thoughtful Brands Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Mota Ventures sees strong sales increase amid COVID-19 Crisis

Mota Ventures (CSE: MOTA-OTCMKTS: PEMTF) CEO Ryan Hoggan joined Steve Darling from Proactive Vancouver to discuss how the company is doing during the Corona Virus crisis and how it has affected sales. Hoggan also told Proactive about a new product line the company has started and how excited...

on 04/01/2020

2 min read